Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Vail

Internal Medicine Greenville, SC Medical Doctor

NPI 1013932359 CMS profile 227660

3611 Pelham Rd, Greenville, SC 29615

Open in the dashboard

General payments

$3,351

210 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Vail of Greenville, SC is reported in the CMS Open Payments database as having received $3,351 across 210 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $256 14
2024 General $741 39
2023 General $1,064 66
2022 General $592 47
2021 General $341 20
2020 General $101 7
2019 General $257 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Vail
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Richard Vail were reported at $256. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Richard Vail Internal Medicine median Middle half National median
2019 $257 $159 $48–$570 $163
2020 $101 $119 $33–$402 $114
2021 $341 $135 $37–$521 $132
2022 $592 $141 $42–$496 $149
2023 $1,064 $149 $45–$519 $160
2024 $741 $154 $47–$537 $164
2025 $256 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $455 35 payments
  2. AbbVie, Inc. $428 34 payments
  3. Amgen Inc. $313 17 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $303 19 payments
  5. AstraZeneca Pharmaceuticals LP $239 12 payments
  6. Lilly USA, LLC $199 18 payments
  7. Medtronic, Inc. $146 2 payments
  8. Exact Sciences Corporation $143 9 payments
  9. Dexcom, Inc. $129 7 payments
  10. Astellas Pharma US Inc $125 7 payments
  11. Other $871 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,351 210 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $303 19 payments
  2. Ozempic $296 19 payments
  3. RYBELSUS $253 16 payments
  4. VRAYLAR $224 16 payments
  5. Repatha $211 13 payments
  6. MOUNJARO $157 14 payments
  7. AIMOVIG $149 9 payments
  8. AIRSUPRA $133 5 payments
  9. UBRELVY $132 11 payments
  10. O-ARM $129 1 payment
  11. Other $2,249 139 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 99 drugs

Part D claims

4,406

Median for Internal Medicine: 777

Drug cost

$279,881

Median for Internal Medicine: $73,373

Branded share of claims

16.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 67 $79,841
Farxiga Dapagliflozin Propanediol Brand 46 $35,113
Multaq Dronedarone Hcl Brand 20 $18,419
Eliquis Apixaban Brand 13 $16,404
Breo Ellipta Fluticasone/Vilanterol Brand 12 $13,859
Xarelto Rivaroxaban Brand 16 $13,175
Trulicity Dulaglutide Brand 11 $10,581
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 14 $10,568
Tresiba Flextouch U-100 Insulin Degludec Brand 20 $10,490
Tresiba Flextouch U-200 Insulin Degludec Brand 14 $8,717

The 10 drugs with the highest cost, of 99 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$100,604

Of which drugs: $9,651

Medicare patients

195

Average age 75

Services billed

2,248

94 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 40%
Ischemic heart disease 28%
Chronic kidney disease 25%
Diabetes 24%
Atrial fibrillation 16%
Cancer 16%
Heart failure 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 78 78 $6,362
Pcv20 vaccine im 90677 Office 11 11 $3,213

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $77
$77 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $61
$61 — —
KRYSTEXXA
  • Amgen Inc. $58
$58 — —
Veozah
  • Astellas Pharma US Inc $58
$58 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record